Finance

ISS-focused company reports $2.9 million second-quarter loss

Published in Hepatitis Weekly, September 6th, 2004

Dynavax Technologies Corp. (DVAX), a biopharmaceutical company focused on the discovery, development, and commercialization of products to treat and prevent allergies, infectious diseases, and chronic inflammatory diseases, reported financial results for the quarter and 6 months ended June 30, 2004.

Dynavax reported a net loss of $2.9 million for the quarter ended June 30, 2004, or $0.12 per basic and diluted share, compared to a net loss of $4.0 million, or $2.23 per basic and diluted share for the same period in 2003. As of June 30, 2004, cash and cash equivalents totaled $74.0 million.

Revenue for the second quarter ended June 30, 2004 was $5.5...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Hepatitis Weekly

Source: Hepatitis Weekly (2004-09-06)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry